STOCKHOLM, Sweden — Moberg Pharma AB has acquired baby care and skin care brand Balmex from Chattem Inc., the U.S. consumer health division of Sanofi, for $3.9 million.

Moberg said early Monday that Balmex products will be sold through the company’s current over-the-counter channel in the United States, mainly in chain drug stores such as CVS/pharmacy, Walgreens and Rite Aid, as well as in mass retailers, such as Walmart, and specialty retailers, including Toys R Us and Buy Buy Baby.

“Adding Balmex to Moberg’s U.S. portfolio is a great fit, within our core area of topical dermatology,” stated Peter Wolpert, chief executive officer of Moberg Pharma AB. “We are continuously evaluating deal opportunities to further leverage our U.S. sales and marketing infrastructure. This deal contributes immediately to our sales and earnings.”

Balmex generates annual net sales of more than $4 million, Moberg reported. The brand’s products include a diaper rash cream, a diaper rash cream stick and a multipurpose healing ointment. An adult care rash cream for soothing skin irritations was launched in 2013.

“We see excellent opportunities to build on the brand equity of Balmex and utilize our innovation engine to further strengthen the future value proposition of the brand to consumers and retailers,” commented Jeff Vernimb, general manager of Moberg Pharma North America.

Other OTC brands in Moberg Pharma’s portfolio include Kerasal, Kerasal Nail, Jointflex, Domeboro, Vanquish and Fergon.